Business Context and Reporting Period
This Form 8-K Current Report was filed by AcelRx Pharmaceuticals, Inc. (ACRX) on March 30, 2021. The filing discloses corporate governance changes, specifically the appointment of a new director and revisions to the Non-Employee Director Compensation Policy.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on corporate governance and compensation arrangements.
Material Changes
- Board Appointment: Marina Bozilenko was appointed as a Class III director, effective March 30, 2021, serving until the 2023 annual meeting.
- Board Composition: The Board size was fixed at nine directors, divided into three classes of three directors each.
- Committee Assignment: Ms. Bozilenko was initially assigned to the Finance and Strategic Transactions Committee (FAST Committee).
- Compensation Policy Revision: Effective April 1, 2021, FAST Committee members will receive an annual retainer of $10,000, with the Chair receiving $20,000.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details the background of the new director, Ms. Bozilenko, noting her experience as a Strategic Advisor at William Blair & Company and her prior roles in biotechnology investment banking. An indemnification agreement was executed to protect Ms. Bozilenko against liabilities arising from her service.
Important Facts for Investor Verification
- Equity Grant: Ms. Bozilenko received a stock option for 30,000 shares at an exercise price of $1.61 and 15,000 restricted stock units.
- Related Party Transactions: The filing explicitly states there are no transactions requiring disclosure under Item 404(a) of Regulation S-K involving Ms. Bozilenko.
- Press Release: A press release announcing the appointment was issued on March 31, 2021, and is filed as Exhibit 99.1.
- Company Name Discrepancy: The request metadata lists "TALPHERA, INC.", but the filing text identifies the registrant as "ACELRX PHARMACEUTICALS, INC."